Skip to main content
. 2000 Jul 5;97(14):7969–7974. doi: 10.1073/pnas.97.14.7969

Figure 2.

Figure 2

(A) T cell activation assay with the recombinant HLA-A1–MAGE-A1 complexes. Microwells were coated with the indicated concentrations of HLA-A1–MAGE-A1 (A1MA1) or HLA-A2–MAGE-A3 (A2MA3) complexes, and washed. CTL clones 82/30 (anti-HLA-A1–MAGE-A1) or 413/13 (against a peptide presented on HLA-A2 molecules) were added at 3,000 cells per well. After 24 h, the concentration of TNF present in the culture medium was measured by testing its cytotoxicity on the TNF-sensitive WEHI-164c13 cells. (B) ELISA with anti-HLA mAbs. Equivalent amounts of proteins were coated directly on plastic (striped, aggregates; gray, β2m; and white, complex) or on streptavidin-coated plastic (black, biotinylated complex) and binding of several mAbs was tested. PBS, no antibody; W6/32, mAb W6/32HL binding to heavy chain–β2m dimers; HK, inactive mutant of W6/32HK; HB28, mAb binding to β2m; HC-A2, mAb binding to a nonconformational epitope of HLA molecules; and TÜ114 and TÜ155, two conformation-sensitive mAbs.